Humaid O Al-Shamsi1, Abdulaziz Al Farsi1, Mahraz Anjum1, Hua Shen1, Kevin Zbuk1, Richard J Cook1, Lori-Ann Linkins1, Pierre Major1. 1. 1 Department of Oncology, McMaster University, Hamilton, Ontario, Canada ; 2 Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada ; 3 Department of Medicine, Sheikh Zayed Military Hospital, Abu Dhabi, United Arab Emirates ; 4 Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Abstract
OBJECTIVE: To determine the incidence and risk factors for thrombotic events (TEs) in patients with metastatic colorectal cancer (mCRC) who received bevacizumab (BV) and FOLFIRI (leucovorin, fluorouracil and irinotican) compared to FOLFIRI alone. METHODS: Single institution retrospective study of 450 mCRC patients who received either BV plus FOLFIRI or FOLFIRI alone between April 2004 and August 2012. Demographics, TE risk factors, and treatment data were abstracted from patients' records. Multivariate analysis was used to identify factors that contributed to thromboembolism. RESULTS: Two-hundred-sixty-one mCRC patients received BV plus FOLFIRI [64.8% males, mean body mass index (BMI) of 27.6] compared to 189 control patients who received FOLFIRI alone (61.9% males, BMI 27.2). The incidence of TEs was 14.9% in the BV plus FOLFIRI group, compared to 15.9% in the control group. Multivariate analysis controlling for age, BMI, gender, malignancy, metastatic sites, line of treatment, and risk factors did not suggest a significant increase in the risk of TE with the addition of BV (OR =0.83 95% CI: 0.40-1.70; P=0.602). No difference in the site of TEs was observed between the treatment groups. The only statistically significant risk factor for thrombosis in the FOLFIRI plus BV group was increased BMI (OR =1.05; 95% CI: 1.01-1.10; P=0.01). CONCLUSIONS: This study does not support a significant increase in the risk of TE in patients with mCRC who received BV in addition to FOLFIRI. Increased BMI may be a risk factor for thrombosis in patients treated with BV.
OBJECTIVE: To determine the incidence and risk factors for thrombotic events (TEs) in patients with metastatic colorectal cancer (mCRC) who received bevacizumab (BV) and FOLFIRI (leucovorin, fluorouracil and irinotican) compared to FOLFIRI alone. METHODS: Single institution retrospective study of 450 mCRC patients who received either BV plus FOLFIRI or FOLFIRI alone between April 2004 and August 2012. Demographics, TE risk factors, and treatment data were abstracted from patients' records. Multivariate analysis was used to identify factors that contributed to thromboembolism. RESULTS: Two-hundred-sixty-one mCRC patients received BV plus FOLFIRI [64.8% males, mean body mass index (BMI) of 27.6] compared to 189 control patients who received FOLFIRI alone (61.9% males, BMI 27.2). The incidence of TEs was 14.9% in the BV plus FOLFIRI group, compared to 15.9% in the control group. Multivariate analysis controlling for age, BMI, gender, malignancy, metastatic sites, line of treatment, and risk factors did not suggest a significant increase in the risk of TE with the addition of BV (OR =0.83 95% CI: 0.40-1.70; P=0.602). No difference in the site of TEs was observed between the treatment groups. The only statistically significant risk factor for thrombosis in the FOLFIRI plus BV group was increased BMI (OR =1.05; 95% CI: 1.01-1.10; P=0.01). CONCLUSIONS: This study does not support a significant increase in the risk of TE in patients with mCRC who received BV in addition to FOLFIRI. Increased BMI may be a risk factor for thrombosis in patients treated with BV.
Authors: N C Tebbutt; F Murphy; D Zannino; K Wilson; M M Cummins; E Abdi; A H Strickland; R M Lowenthal; G Marx; C Karapetis; J Shannon; D Goldstein; S S Nayagam; R Blum; L Chantrill; R J Simes; T J Price Journal: Ann Oncol Date: 2011-01-27 Impact factor: 32.976
Authors: Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza Journal: N Engl J Med Date: 2011-12-29 Impact factor: 91.245
Authors: Herbert I Hurwitz; Louis Fehrenbacher; John D Hainsworth; William Heim; Jordan Berlin; Eric Holmgren; Julie Hambleton; William F Novotny; Fairooz Kabbinavar Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: T Meyer; L Robles-Carrillo; T Robson; F Langer; H Desai; M Davila; M Amaya; J L Francis; A Amirkhosravi Journal: J Thromb Haemost Date: 2008-10-30 Impact factor: 5.824
Authors: Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Howard S Hochster; Lowell L Hart; Ramesh K Ramanathan; Barrett H Childs; John D Hainsworth; Allen L Cohn; Lucas Wong; Louis Fehrenbacher; Yousif Abubakr; M Wasif Saif; Lee Schwartzberg; Eric Hedrick Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: F S Falvella; C Cremolini; R Miceli; F Nichetti; S Cheli; C Antoniotti; G Infante; A Martinetti; F Marmorino; E Sottotetti; R Berenato; M Caporale; A Colombo; F de Braud; M Di Bartolomeo; E Clementi; F Loupakis; F Pietrantonio Journal: Pharmacogenomics J Date: 2016-03-22 Impact factor: 3.550
Authors: Steven Ades; Bhargavi Pulluri; Chris E Holmes; Inder Lal; Santosh Kumar; Benjamin Littenberg Journal: Cancer Med Date: 2022-02-06 Impact factor: 4.711